Biohaven Launches Pivotal Phase 3 Trial for Graves' Disease Therapy

The trial, which involves approximately 300 adults, marks the first time a MoDE (Molecular Degrader of Extracellular proteins) platform therapy has reached this stage of clinical development. Unlike current standards of care—such as surgery, radioactive iodine, or antithyroid medications—BHV-1300 leverages the body's natural hepatic clearance pathways to selectively eliminate TSHR-IgG1 autoantibodies. These pathogenic proteins are responsible for overstimulating the thyroid receptor, driving hyperthyroidism and associated complications like thyroid eye disease.

Early data from Phase 1b testing provided a foundation for the current study, showing that the molecule reduced pathogenic autoantibodies by more than 80% while normalizing thyroid hormone levels. The drug is administered via a self-operated autoinjector, offering a departure from traditional clinical interventions. If successful, the treatment would represent a significant shift in precision immunology, moving away from symptom management toward the direct removal of the specific proteins causing the autoimmune disorder.